Venous thromboembolism market to grow to $3.7 billion by 2025; report

The therapeutics market for venous thromboembolism (VTE), a condition which comprises deep vein thrombosis and pulmonary embolism, is set to rise from $2.8 billion in 2015 to $3.7 billion by 2025, representing a compound annual growth rate (CAGR) of 2.89%.

According to research and consulting firm GlobalData’s latest report, this steady growth, which will occur across the seven major markets of the USA, France, Germany, Italy, Spain, the UK, and Japan, will be driven primarily by the rise in sales surrounding the VTE primary prophylaxis space, which is projected to increase from $2.4 billion in 2015 to $3.5 billion by 2025, at a CAGR of 4.01%.

Michela McMullan, GlobalData’s analyst covering cardiovascular and metabolic disorders, explains: “Novel oral anticoagulants (NOACs), which are used to prevent and treat VTE, will primarily drive the market, and represent important advances over warfarin, a cheap and established anticoagulant. This is because NOACs do not require routine blood monitoring or dose adjustments, have fewer drug-drug interactions, do not produce major dietary effects, and in terms of efficacy and safety, have been proven to be non-inferior, if not superior, compared with warfarin.”